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Abstract
Rotavirus is the main cause of viral gastroenteritis in young children. Therefore, the development of inexpensive antiviral
products for the prevention and/or treatment of rotavirus disease remains a priority. Previously we have shown that a
recombinant monovalent antibody fragment (referred to as Anti-Rotavirus Proteins or ARP1) derived from a heavy chain
antibody of a llama immunised with rotavirus was able to neutralise rotavirus infection in a mouse model system. In the
present work we investigated the specificity and neutralising activity of two llama antibody fragments, ARP1 and ARP3,
against 13 cell culture adapted rotavirus strains of diverse genotypes. In addition, immunocapture electron microscopy
(IEM) was performed to determine binding of ARP1 to clinical isolates and cell culture adapted strains. ARP1 and ARP3 were
able to neutralise a broad variety of rotavirus serotypes/genotypes in vitro, and in addition, IEM showed specific binding to
a variety of cell adapted strains as well as strains from clinical specimens. These results indicated that these molecules could
potentially be used as immunoprophylactic and/or immunotherapeutic products for the prevention and/or treatment of
infection of a broad range of clinically relevant rotavirus strains.
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Introduction
Rotavirus is a non-enveloped, icosahedral virus of the Reoviridae
family containing a genome of 11 segments of double stranded
RNA (dsRNA). Recently, it has been estimated that each year,
rotavirus causes more than a 100 million episodes of gastroenteritis
which results in 25 million clinic visits, 2 million hospitalizations,
and more than 611,000 deaths in children below 5 years of age
[1]. By 5 years of age, nearly every child worldwide will have had
at least one episode of rotavirus gastroenteritis [2]. Children in
developing countries account for 82% of rotavirus deaths.
Therefore, rotavirus remains the most important cause of severe
and life threatening viral gastroenteritis and dehydrating diarrhoea
in young children worldwide [3,4,5].
Rotavirus replicates in mature enterocytes of the small intestine
leading to a reduction of enterocyte-specific gene expression and
an induction of virus gene expression and inflammatory mediators
and is thought to be a multi-factorial process [6,7] which include a
reduction in epithelial surface area, replacement of mature
enterocytes by immature cells, down regulation of genes involved
in digestion and absorption of nutrients, salt and water, an osmotic
effect resulting from incomplete absorption of carbohydrates from
the intestinal lumen and the secretion of intestinal fluid and
electrolytes through activation of the enteric nervous system
(reviewed in [8,9,10], Despite the prevalence of rotavirus
diarrhoeal disease and extensive studies in different animal
models, rotavirus pathogenesis is still not completely understood.
Rotaviruses are currently divided into seven serotypes (Rotavi-
rus A–G). They exhibit broad genetic and antigenic diversity due
to reassortment among rotavirus strains and the accumulation of
point mutations in the surface protein genes. Group A rotaviruses
are the major human pathogens, and have been further
categorised on the basis of the outer capsid proteins, VP4 (P-
type) and VP7 (G-type), and the intermediate layer protein VP6
(subgroups [SG]). Currently, there are 35 P-types and 27 G-types
[11,12,13,14] and four VP6 SGs [15,16] recognised. As well as
showing different G and P types and a variety of combinations of
these, there is also intratypic variation. The incidence and
distribution of group A rotavirus genotypes varies between
geographical areas during a rotavirus season, and from one season
to the next [17]. Globally, G1P [8], G2P [4], G3P [8], G4P [8]
and G9P [8] are the most common G and P types of rotavirus
causing disease in humans. However, the introduction of
molecular typing methods has revealed the existence of other G
and P types such as G5, G6, G8, G10, G12, P [6] and P [11]
causing infection in humans which have most likely emerged
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through zoonotic transmission. Zoonotic transmission and the
ability of rotaviruses to reassort following double infections provide
the potential for the emergence of novel strains [18].
Several oral, live-attenuated vaccines have been developed in
recent years. Two of them have been licensed and are in use in
several countries in universal vaccination programmes. There is, to
date, no satisfactory therapeutic means for controlling rotavirus
disease, and alternative therapies are thus needed urgently. Also,
prophylactic measures, in particular in a high risk setting (for
example, outbreaks, the immunocompromised, etc) may be a
useful addition to current rotavirus prevention strategies. The
usefulness of any such treatment will be determined to a great
extent on their ability to be effective against the broad spectrum of
rotavirus types commonly circulating in the population worldwide.
Previously we have shown that specific antibody fragments
derived from llama heavy chain antibodies (VHH fragments) can
be obtained against different types of antigens [19]. Furthermore,
by using modern biotechnology, these fragments can be produced
in bakers yeast, Saccharomyces cerevisiae, in a cost effective way [20].
It has been demonstrated that monovalent VHH binding domains
can neutralise bacteriophages [21]. Previously, we described the
production of anti-rotavirus VHH fragments after immunising a
llama with the rhesus rotavirus (RRV) [22]. It was demonstrated
that one of these anti-rotavirus VHH fragments (VHH1, now
referred to as Anti-Rotavirus Protein 1 or ARP1) was able to
neutralise RRV in an mouse model system [22]. Furthermore, in a
recent human intervention study ARP1 has been shown to reduce
the stool output in young children with rotavirus diarrhoea with
about 50% (Sarker et al, submitted).
This study describes the ability of ARP1 and ARP3 (derived in
the same manner as ARP1) fragments to bind and neutralise
rotaviruses of different genotypes, including those genotypes found
with the highest incidences in cases of infantile diarrhoea
worldwide. The knowledge obtained from this work may be
useful for the development of compounds able to prevent rotavirus
diarrhoea in young children.
Materials and Methods
Rotavirus strains
For the in vitro neutralization studies, cell culture adapted
rotavirus strains WI61 (G9P [8]) and DS-1 (G2P [4]) were
obtained from the ATCC. The human rotavirus strain Wa (G1P
[8]), one strain of the rhesus rotavirus strain RRV (G3P [3]) and
the simian rotavirus strain SA-11 (G3P [1]) were kindly provided
by Dr. M. Koopmans (RIVM, Bilthoven, The Netherlands). Cell
culture adapted strains ST-3 (G4P [6]), 69M (G8P [10]), RV4
(G1P [8]), F45 (G9P [8]), Va70 (G4P [8]) and P (G3P [8]) were
kindly provided by Dr C. Kirkwood (Murdoch Children’s
Research Institute, Melbourne, Australia), and a second strain of
RRV was obtained from Dr Harold Marcotte of the Karolinska
Institute, Stockholm, Sweden. These strains were cultured
according to the methods previously described [23]. For the
IEM studies, cell culture adapted and human stool samples
containing G1P [8], G2P [4], G3P [8], G4P [8], G9P [6], G9P
[8], G10P [11] and G12P [9] rotavirus strains were used.
Antibody fragments
Llama derived ARP1 and ARP3 raised against a G3P [3]
rotavirus strain were obtained as described in Vaart et al. [22]. A
control fragment from a llama immunized with the hapten antigen
azodye RR6 coupled to BSA, VHH R2, was used throughout
[20]. All 3 fragments were produced in yeast as previously
described [20] and purified from yeast culture medium by ion
exchange chromatography. In brief, the yeast culture medium was
diluted 5 times in 25 mM sodium acetate buffer pH 4.5 (Sigma,
Zwijndrecht, Netherlands) and loaded on a 10 ml Sp-Sepharose
FF column (GE Healthcare, Little Chalfont, UK). Unbound
material was removed by washing with 25 mM sodium acetate
pH 4.5. Bound llama fragment was eluted with 40 mM Na2HPO4
pH 12 (Sigma, Zwijndrecht, Netherlands). The eluted fraction was
brought to the biotinylation buffer (50 mM Ca2CO3 pH 8) using a
PD10 column (GE Healthcare, Little Chalfont, UK).
ARP1, ARP3 and VHH R2 were biotinylated by adding NHS-
biotin (N-Hydroxysuccinimidobiotin in DMSO, Sigma, Zwijn-
drecht, Netherlands) to the llama fragments in a molar ratio of
20:1 (NHS-biotin : llama fragment). Unbound biotin was removed
by dialysis against PBS after incubating on a rotary mixer for
2 hours at room temperature.
Rotavirus neutralisation studies
The rotavirus neutralisation studies were performed indepen-
dently in two laboratories, the Laborotory Pediatrics, Erasmus
MC-Sophia, Rotterdam, The Netherlands, and The Enteric Virus
Unit, Virus Reference Department, Health Protection Agency,
London, UK.
At the Laboratory of Paediatrics, Erasmus MC, CaCo-2
(ATCC, HTB-37) or MA104 (ATCC, CRL-2378.1) cells were
maintained in Dulbecco’s Modified Eagle’s Medium (DMEM,
GibcoBRL, Paisley, Scotland) containing 10% (v/v) foetal calf
serum (FBS, Integro, Dieren, The Netherlands), 100 U/ml
Penicillin, 100 mg/ml Streptomycin and 1% (v/v) non-essential
amino acids (BioWhittacker, Verviers, Belgium) at 37uC and in an
atmosphere of 5% CO2-air.
To test the neutralising activity of the llama antibody fragment
ARP1 and a control antibody (VHH R2), 1.56104 CaCo-2 cells
were plated on heavy Teflon coated microscope slides ( 7 mm,
Cell-line/Erie Scientific, Portsmouth, NH) as described previously
[23]. Cells were rinsed 3 times with culture medium in the absence
of FBS (DMEM-FCS) and incubated with different concentrations
of the llama antibodies for 1 hour at 37uC prior to infection.
Simultaneously, rotavirus was treated for 1 hour at 37uC with
10 mg/ml trypsin (Sigma, Zwijndrecht, Netherlands) diluted in
DMEM-FCS. Subsequently, CaCo-2 or MA104 cells were
inoculated with 100 fluorescent focus forming units (fffu) of
rotavirus in absence or presence of decreasing concentrations of
the llama antibodies (10 mg/ml-0.16 mg/ml in doubling dilutions.
At 15 hours post-inoculation (p.i.), cells were fixed in ice-cold
methanol at 220uC for 10 minutes and stored in phosphate
buffered saline (PBS) pH 7.2. Infectivity was determined by an
indirect immunofluorescence assay (IFA). The methanol-fixed cells
were incubated for 90 minutes at room temperature with the
polyclonal rabbit anti-rotavirus serum (K3ppIV, kindly provided
by Dr. M. Koopmans, RIVM, Bilthoven, The Netherlands)
diluted in PBS (1:1600), rinsed four times with PBS, and stained
for 1 hour with goat anti-rabbit Texas Red conjugated IgG
(Jackson ImmunoResearch Laboratories Inc., West Grove, PA)
diluted in PBS (1:300). Finally, cells were washed extensively and
mounted in Mowiol (Calbiochem, San Diego, CA) containing
2.5% w/v DABCO (1,4-diazabicyclo[2.2.2]octane) and 0.5 mg/ml
DAPI (49,6-diamidino-2-phenylindole dihydrochloride:hydrate;
Sigma-Aldrich, Zwijndrecht, Netherlands). Fluorescence was
viewed with a Nikon Eclipse E800 microscope. The number of
infected cells in the antibody-treated and control cells was
expressed as a percentage of the average number of infected cells
in the control cell cultures. Each titration experiment was
performed at least twice.
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At the Enteric Virus Unit, Health Protection Agency, London,
UK, MA104 (ATCC, CRL-2378.1) cells were maintained in
MEM (Life Technologies, Paisley, UK) supplemented with 10%
foetal calf serum (Life Technologies, Paisley, UK) and gentamicin
(Life Technologies, Paisley, UK) (50 mg/L). One hundred
microliters of MA104 cells at a concentration of 16105 cells/ml
were seeded onto 96-well cell culture plates (Cellstar, Greiner,
Gloucestershire, UK) and incubated at 37uC, in an atmosphere of
5% CO2-air until cells were confluent (24–36 hours). Media was
replaced with 100 ml serum-free media the day before infection
and the cells were incubated overnight at 37uC in 5% CO2-air.
Rotavirus strains were activated with porcine-trypsin (Sigma,
Dorset, UK) at 5 mg/ml by incubation at 37uC for 30 minutes
prior to infection. Trypsin-activated virus was diluted to 100 fffu
per 100 ml (16103 fffu/ml) in a total volume of 5 ml serum-free
media. A total of 100 ml (or 100 fffu) of activated virus was mixed
with 100 ml of ARP1, ARP3 or VHH R2 antibodies in serial
twofold dilutions in a separate dilution plate to give final antibody
concentrations from 10 mg/ml to 0.16 mg/ml and incubated at
37uC for 1 hour. Experiments were performed in duplicate, and a
control with no antibody was included in duplicate in each
experiment. After removing media from the 96-well plate
containing the MA104 cells, 200 ml of virus/VHH mix were
added to the cells, the plates were sealed and centrifuged at
10006g for 20 minutes. The plate-seal was removed and the
inoculated cells were incubated overnight at 37uC in 5% CO2-air.
Rotavirus infected cells were detected by immuno-fluorescence
(IF). Cells were washed with 300 ml of PBS after removal of the
inoculum and then fixed with methanol (VWR, West Sussex, UK)
before air drying. A total of 100 ml/well of an anti-VP6 rotavirus
monoclonal antibody (AMS Biotechnology, Abingdon, UK);
diluted 1:200 in PBS) was added and incubated at 37uC for
30 minutes. Cells were washed 3 times with PBS-Tween20
(0.05%) before 100 ml of a rabbit anti-mouse IgG FITC (Dako,
Ely, UK) diluted 1:20 in PBS with 0.005% Evans Blue
(Euroimmun, Pontypool, UK) as a counterstain was added. Plates
were incubated 30 minutes at 37uC followed by 3 washes with
PBS-Tween20. Finally, cells were allowed to air dry and 50 ml of
10% glycerol (Sigma, Dorset, UK) in saline were added to prevent
desiccation. Cells were visualised using an epifluorescence inverted
microscope (Nikon Eclipse) and the number of fluorescent foci
recorded. Experiments were conducted on at least 2 separate
occasions for each strain and antibody concentration, and the
antibody concentration needed to reduce the number of
fluorescent foci by 50% was calculated for each antibody/rotavirus
strain tested
SDS-PAGE and Western blotting
Five millilitres of cell culture grown rotavirus was clarified by
centrifugation at 10006g, 10 minutes, the supernatant ultra-
centrifuged at 48,0006g, 45 minutes (Optima L-100 XP
Ultracentrifuge, Beckman Coulter, USA) and the virus resus-
pended in 100 ml MEM (Life Technologies, Paisley, UK).
Recombinant VP6 and VP7, expressed in a baculovirus/insect
cell expression system and lyophilised (in house and in
collaboration with Baylor College of Medicine, Houston, TX)
were resuspended to 1 mg/ml each. Uninfected MA104 cells
(used to propagate the virus) were included as a negative
control. A total of 6.25 ml 46NuPage LDS Sample Buffer (Life
Technologies, Paisley, UK) and 2.5 ml 106 NuPage Reducing
Agent (Life Technologies, Paisley, UK) were added to 16.5 ml
sample, and incubated at 70uC, 10 minutes. Twenty five
microlitres of denatured protein sample was separated on a 4–
12% SDS-PAGE gel (Life Technologies, Paisley UK) at 100 V,
10 minutes then 150 V, 1 hour in 16NuPage MOPS Running
Buffer (Life Technologies, Paisley, UK). Proteins were trans-
ferred from the gel to a nitrocellulose membrane (GE
Healthcare Life Sciences, Buckinghamshire, UK) in 16NuPage
Transfer Buffer (Life Technologies, Paisley, UK) with NuPage
Antioxidant (Life Technologies, Paisley, UK) and 10% meth-
anol (VWR, West Sussex, UK) for 1 hour at 30 V.
For the Western Blotting, the membrane was blocked in 5%
milk in PBS-Tween20 at 37uC, 1 hour. The membrane was then
incubated with either 5 mg/ml biotinylated ARP1, ARP3,
VHHR2 or 1:2000 monoclonal mouse anti-VP6 (AMS Biotech-
nology, Abingdon, UK) in 5% milk in PBS-Tween20 at 37uC,
1 hour. The membrane was then washed in PBS-Tween20 3
times, 10 minutes/wash and incubated with either 1:5000 alkaline
phosphatase-conjugated streptavidin (Promega, Southampton,
UK), for membranes treated with biotinilated primary antibodies
or 1:1000 goat anti-mouse HRP (Dako, Ely, UK), for membranes
treated with the mouse monoclonal antibodies, in 5% milk in PBS-
Tween20 at 37uC, 1 hour. The membrane was then washed in
PBS-Tween20 3 times, 10 minutes/wash. Membranes were
developed using the appropriate chemilluminescence reagent,
either CDP-Star (Life Technologies, Paisley, UK) for the alkaline
phosphatase or ECL Reagent (GE Healthcare, Little Chalfont,
UK) for the HRP.
Immune electron microscopy - Immune capture
Formvar-coated copper grids were coated by floating on a
solution of streptavidin (Prozyme, Hayward, CA, USA) (5 mg/ml)
in distilled water overnight. Grids were washed by floating on
distilled water, blotted and floated onto a 1:10 or 1:20 dilution of
the biotinylated antibody (ARP1 or control VHH R2). The grid
was incubated for 1 hour at 37uC and washed as before. The grids
were floated onto 10% suspensions of rotavirus positive faeces or
undiluted cell culture supernatants and incubated at 37uC for
1 hour. Grids were washed twice and floated onto 3% phospho-
tungstic acid (pH 6.3) (Agar Scientific Ltd, Essex, UK) for
1 minute, blotted and allowed to dry in air before examination
in the JEOL JEM 1200EX electron microscope. The number of
virus particles seen in 5 grid squares was determined and the
results expressed as particles/grid square. Specific reactivity was
inferred from an increase ($4 fold) in the number of particles/grid
square in the grid coated with ARP1 when compared to the
control grid.
Results
In vitro neutralising activity of the ARP1 and ARP3
antibody fragments
The initial experiments carried out in The Netherlands with
strains Wa, SA11, RRV, or WI61 were performed in CaCo-2
cells, and in MA104 for strain DS-1, and only neutralising activity
of ARP1 was determined with VHH R2 as control. In subsequent
experiments carried out in the UK, in MA104 cells, both ARP1
and ARP3 rotavirus-specific antibodies were tested in addition to
the control VHH R2.
The combined results are shown in Table 1. ARP1 showed
neutralising activity with all strains but SA11 and one of the RRV
strains. ARP3 showed similar neutralising activity to ARP1 with
the strains that were tested. The concentration of ARP1 or ARP3
required to give a 50% reduction in fffu was different among
strains and ranged from 0.63 mg/ml to 5 mg/ml (Table 1 and
Figure 1). No neutralising effect in any of the assays was detected
with the control antibody VHH R2.
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Characterization of the binding specificity of the Llama
antibody
Immune-EM showed that ARP1 bound rotavirus strains of
different genotypes from clinical samples including the recently
emerged G8, G10 and G12 strains (Table 2). Binding was also
demonstrated for those cell culture adapted rotavirus strains for
which ARP1 showed neutralisation activity. Two different strains
of RRV were used, whilst one showed binding, the other did not,
and these results were in agreement with the inability of the
rotavirus-specific antibodies to neutralise one of the RRV strains.
No significant binding was observed for strains SA11, P and RV4.
Determination of proteins involved in antibody binding
by Western blotting
In order to identify the viral protein recognised by these
antibody fragments, rotavirus strains RRV, SA11, ST-3, 69 M,
Va70 and F45, were subjected to SDS-PAGE. Recombinant VP6
and VP7 proteins derived from clinical isolates and expressed in a
baculovirus/insect cell system were included as controls. The
results showed that both ARP1 and ARP3 recognised bands
corresponding to those also recognised by the anti-VP6 monoclo-
nal antibody, representing polymeric VP6, including the recom-
binant VP6 protein (Figure 2). Neither antibody reacted with any
other rotavirus protein, nor did VHH R2 show any reactivity.
Discussion
Llama antibody fragments ARP1 and ARP3, obtained after
immunisation of a llama with RRV G3P [3], were tested for
binding and/or neutralising activity towards a broad range of
different rotavirus genotypes that were representative of the most
common and recently emerged strains worldwide.
Results obtained in the neutralisation assays show that ARP1
neutralised infectivity with rotavirus strains Wa (G1P [8]), DS-1
(G2P [4]), WI-61 (G9P [8]), 69M (G8P [10]), F45 (G9P [8]), Va70
(G4P [8]), RV4 (G1P [8]), M37 (G1P [6]), ST-3 (G4P [4]) and P
(G3P [8]), although there were differences in the concentration of
antibody required to achieve a 50% reduction in fffu. ARP3
demonstrated similar neutralisation activity to ARP1, with one
exception. ARP3 showed greater neutralising activity against
strain P than ARP1, and lower concentrations were required to
achieve a 50% reduction in fffu. The control antibody did not
neutralise any of the tested rotavirus strains, indicating the
neutralising activity was specific for ARP1 and ARP3. Neither
ARP1 nor ARP3 were able to neutralise SA11. Interestingly, two
RRV strains sourced from different laboratories exhibited different
binding patterns and neutralisation results. It is unclear whether
these differences are due to the differences in the cell line used for
virus propagation and neutralisation assays, or whether the strains
represent different clones, one of which may have a mutation or
mutations in an epitope recognised by these antibody fragments.
Previously, Pant et al [24] demonstrated neutralising ability of
ARP1 both in vitro and in vivo in a mouse model, and reported that
125 ng/ml of VHH1 (ARP1) was able to show 80% reduction in
infection in cell culture using MA104 cells. Detailed characterisa-
tion through genome sequencing and comparison of the deduced
amino acid sequences of the viral proteins of these two strains may
reveal mutations responsible for the observed differences and
could also provide some insight into the viral protein that is
recognised by these llama antibody fragments.
It has been suggested both in this study, and in other published
works, that VP6 is recognised by ARP1, but the rotavirus
protein(s) involved viral neutralisation has yet to be fully
characterised. Immune EM experiments using EDTA-treated
virus particles (to remove the outer layer and expose the VP6) have
been inconclusive in elucidating the exact mechanism by which
virus neutralisation occurs (data not shown). Previous work has
showed that ARP1 and ARP3 recognised different epitopes as they
do not compete (H. Marcotte, personal communication). The
broad reactivity and neutralising capacity of these antibody
fragments indicates that they recognise cross-reactive epitopes.
The outer layer proteins VP7 and VP4 both contain neutralising
Table 1. Infection neutralisation of different rotavirus strains with rotavirus-specific antibody fragments ARP1 and/or ARP3.
Infection neutralisation with antibody fragments
RV strain Genotype Cell line ARP1
conc. for $50%
reduction fffu ARP3
conc. for $50%
reduction fffu VHH R2
Wa G1P [8] CaCo-2 Yes 0.63 mg/ml NT No
SA11 G3P [1] CaCo-2 No NT No
RRV (RIVM strain) G3P [3] CaCo-2 Yes 2.5 mg/ml NT No
WI61 G9P [8] CaCo-2 Yes 2.5 mg/ml NT No
69M G8P [10] MA104 Yes 0.63 mg/ml Yes 0.63 mg/ml No
F45 G9P [8] MA104 Yes 0.63 mg/ml Yes 0.63 mg/ml No
Va70 G4P [8] MA104 Yes 0.63 mg/ml Yes 0.63 mg/ml No
RV4 G1P [8] MA104 Yes 1.25 mg/ml Yes 1.25 mg/ml No
M37 G1P [6] MA104 Yes 1.25 mg/ml Yes 1.25 mg/ml No
DS1 G2P [4] MA104 Yes 5.0 mg/ml Yes 5.0 mg/ml No
ST-3 G4P [4] MA104 Yes 5.0 mg/ml Yes 5.0 mg/ml No
P G3P [8] MA104 Yes 5.0 mg/ml 2.5 mg/ml No
RRV (KI strain) G3P [3] MA104 No No No
SA11 G3P [1] MA104 No No No
A summary of neutralisation of different tissue-culture adapted rotavirus strains with ARP1 and/or ARP3, with the concentration of antibody required to achieve a 50%
reduction in fffu. VHH R2, a non-related llama antibody fragment, was used as a control.
doi:10.1371/journal.pone.0032949.t001
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epitopes, but these tend to be type-specific. The middle layer
protein, VP6, is the most abundant and immunodominant viral
protein, and contains the group and subgroup determining
epitopes, and mostly cross-reactive epitopes; for this reason
antibodies that recognise this protein are often used in diagnostic
immunocapture assays.
Western blots were performed using biotinylated ARP1, ARP3
and VHH R2, and a variety of rotavirus strains that were
neutralised by ARP1 and ARP3 as well as the SA11 and RRV
strains that were not neutralised. ARP1 and ARP3 recognised the
polymeric VP6 of all strains tested, including SA11 and RRV.
This suggests that binding may not necessarily correlate with
neutralising activity, and that neutralisation may be dependent on
the recognition of a conformational epitope which may also be
influenced by the adjacent proteins VP7 and VP4, similar to
previously reported phenotypic changes for VP4 depending on the
VP7 context [25].
The immune-capture experiments indicated that the ARP1
bound to a range of rotavirus genotypes. Interestingly, of the
rotavirus strains derived from faecal samples, the antibody was
most reactive against G3P [8], whereas reactivity was highest
against Wa (G1P [8]) when the cell culture supernatants were
examined, when compared against the VHH R2 control. Also,
several of the cell culture adapted strains did not show
significant reactivity with ARP1 in immune EM although their
infectivity was neutralised in cell culture. This apparent
contradiction in the results is likely to be due to low viral titres
in some of the cell culture supernatants as reflected by the
particle counts obtained in the absence of antibodies. Typically,
viral loads as high as 1011–1012 virus particles per gram of faeces
are found in clinical samples during the acute phase of disease,
whereas typical viral loads achieved in cell culture range from
103–107/ml. For example, for those strains for which the results
of the neutralisation and immune-EM assays did not provide a
good correlation, the titres were 3.86103 fffu/ml, 9.16104 fffu/
ml and 2.86105 fffu/ml for strains RV4, P and 69 M,
respectively.
For some time it was thought that antibodies directed against
VP6 have no neutralising activity, however, evidence to the
contrary has been mounting. Anti-VP6 secretory IgA binds to
rotavirus double-layered particles conferring protection by
intracellular neutralisation following transcytosis in mice
[26,27,28]. Recently, llama-derived antibodies that bind specif-
ically to rotavirus VP6 have been shown to neutralise infection
with a variety of rotavirus genotypes in vitro, and in a neonatal
mouse model [24]. The mechanism by which the llama
antibodies neutralise infection is not yet understood, but
Garaicoechea et al speculated that the VP6-specific VHH may
block VP6 interaction with a cellular receptor [29,30] or induce a
conformational change which prevents attachment of the virus
particle. The neutralising capacity of these antibodies may relate
to their phenotypic small size, as bivalent VHH antibodies
showed much reduced neutralising activity compared to the
monovalent VHH [29].
Currently there is no specific therapy to treat rotavirus disease
other than oral or intravenous rehydration solution. However, in
the areas of the world where rotavirus disease takes the biggest
toll, the use of oral rehydration solution is still disappointingly
low, and rotavirus infection is still a major cause of mortality in
young infants. Several oral vaccines have been developed
recently, and these are highly efficacious in preventing severe
disease. However, questions remain about their effectiveness in
the poorest regions of the world where oral vaccines often fail to
induce protection due to concomitant infections in malnourish-
ment children. In these populations many doses are often
required, with concomitant cost and logistical implications, but
Figure 1. Neutralisation of cell culture adapted rotavirus strains in MA104 cells. Neutralisation experiments were performed using
rotavirus-specific antibody fragments ARP1 and ARP3 and control antibody VHH R2. Bars represent percentage of infected cells (fffu) compared with
absence of any antibody. A 95% confidence interval is shown by the error bar. A dashed line indicating 50% reduction in fffu is highlighted, and the
antibody concentration at which this is achieved is boxed. Concentration of ARP or VHH R2 is expressed in mg/ml on the X-axis in each graph.
doi:10.1371/journal.pone.0032949.g001
Table 2. Immune EM with rotavirus strains of different
genotypes from clinical samples or cultured reference
rotavirus strains.
Particles per grid square
Sample Genotype ARP1 VHH R2
Ratio ARP1:
VHH R2
Rotavirus from Clinical samples
Sample 1 G1P [8] 168 12 14
Sample 2 G1P [8] 30 5 6
Sample 3 G1P [8] 91 13 7
Sample 4 G2P [4] 40 ,1 40
Sample 5 G3P [8] 1600 30 53.3
Sample 6 G4P [8] 47 ,1 47
Sample 7 G9P [6] 217 25 10.8
Sample 8 G9P [8] 74 3 24.7
Sample 9 G12P [9] 77 13 5.9
Sample 11 G10 P [11] 30 2 15
Sample 12 G10 P [11] 116 ,1 $116
Sample 12 G10 P [11] 22 1 22
Cell culture Fluid
Wa G1P [8] 330 ,1 330
WI61 G9P [8] 11 14 0.78
DS1 G2P [4] 227 3 75.7
RRV (RIVM Strain) G3P [3] 455 27 16.9
UP3 G9P [6] 12 ,1 12
SA11 G3P [1] 2 ,1 2
SA11 G3P [1] 5 ,1 $5
RV4 G1P [8] 3 2 1.5
P G3P [8] 1 4 0.3
ST-3 G4P [6] 82 1 82
Va70 G4P [8] 88 1 88
69M G8P [10] 6 2 3
F45 G9P [8] 10 ,1 $10
RRV (KI strain) G3P [3] 5 24 0.2
Two different antibody batches were used, one batch was used at 0.14 mg/ml
and the results are shown in italics, the second batch was used at 0.15 mg/ml.
The number of virus particles seen in 5 grid squares was determined and the
results expressed as particles/grid square. Specific reactivity was inferred from
an increase ($4 fold) in the number of particles/grid square in the grid coated
with ARP1 when compared to the control grid.
doi:10.1371/journal.pone.0032949.t002
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also, as rotavirus infections occur very early in life; children are
exposed to natural rotavirus infection before vaccine-induced
protection can be achieved. Recent vaccine trials in Africa and
Bangladesh showed that the efficacy of the current live-
attenuated vaccines is significantly lower to that observed in
developed countries [31,32]. However, it is considered that even
with this reduced efficacy, they are expected to have a major
impact in the reducing mortality and SAGE recommends the
inclusion of rotavirus vaccination of infants into all national
immunization programmes (http://www.who.int/wer/2009/
wer8423.pdf).
Several studies have been performed following passive
immunisation strategies using bovine colostrum [33,34] or
hyperimmunised chicken egg yolk immunoglobulin [35]. These
studies indicated the possible benefits that can be achieved
through anti-rotavirus prophylaxis. However, product yield and
cost remain the limiting factors. An antiviral chemotherapeutic
agent has also been trialled for the treatment of rotavirus
diarrhoeal disease, acetorphan (racecadotril). This encephalinase
inhibitor has in fact been shown to be effective in reducing the
stool output of young children with acute diarrhoea [36]. Finally,
probiotics have attracted a renewed interest in last few years,
particularly focusing on their effects in treating and preventing
diarrheal diseases [37]. However, costs will also remain a
limiting factor for the broad use of these promising new
developments in developing countries, where they are most
needed. As a consequence, there is no satisfactory prophylactic
(or therapeutic) means of controlling rotavirus infection, and
alternative therapies are still needed. Here we have provided
evidence that the two llama-derived antibody fragments, ARP1
and ARP3, have the potential to be used as new antiviral
prophylactic or therapeutic products and may provide a valuable
complementary prophylactic measure, particularly for those
populations in which the efficacy of the live attenuated vaccines
is suboptimal. ARP1 has previously been shown to reduce
rotavirus-induced diarrhoea in the mouse model [22]. However,
only human intervention studies currently under way will
determine their usefulness in the prevention or treatment of
rotavirus-induced diarrhoeal disease.
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Figure 2. Western blots. Western blots were performed with either [a] monoclonal mouse anti-VP6 or [b] ARP1-biotin. Concentrated cell adapted
rotaviruses were run on an SDS-PAGE gel, transferred to a nitrocellulose membrane, and blotted with appropriate antibodies.
doi:10.1371/journal.pone.0032949.g002
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